CMXC Stock Overview
Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney functions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Cell MedX Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.032 |
| 52 Week High | US$0.93 |
| 52 Week Low | US$0.000001 |
| Beta | 32.82 |
| 1 Month Change | 33.33% |
| 3 Month Change | 3.23% |
| 1 Year Change | 3,199,900.00% |
| 3 Year Change | -88.49% |
| 5 Year Change | -81.18% |
| Change since IPO | -68.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CMXC | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -33.3% | 1.6% | 1.0% |
| 1Y | 3,199,900.0% | -1.4% | 21.9% |
Price Volatility
| CMXC volatility | |
|---|---|
| CMXC Average Weekly Movement | 34.5% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | David Jeffs | cellmedx.com |
Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company also develops eBalance Home and eBalance Pro System for temporary relief of shoulder, waist, back, neck, arms, and legs.
Cell MedX Corp. Fundamentals Summary
| CMXC fundamental statistics | |
|---|---|
| Market cap | US$9.51m |
| Earnings (TTM) | -US$96.91k |
| Revenue (TTM) | US$74.00 |
Over9,999x
P/S Ratio-98.1x
P/E RatioIs CMXC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMXC income statement (TTM) | |
|---|---|
| Revenue | US$74.00 |
| Cost of Revenue | US$545.00 |
| Gross Profit | -US$471.00 |
| Other Expenses | US$96.44k |
| Earnings | -US$96.91k |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00033 |
| Gross Margin | -636.49% |
| Net Profit Margin | -130,962.16% |
| Debt/Equity Ratio | -43.8% |
How did CMXC perform over the long term?
See historical performance and comparison